3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
3
Stomach Neoplasms
2
Sarcoma, Synovial
2
Neuroendocrine Tumors
2
Liposarcoma
2
Glioblastoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Bone Neoplasms
2
Astrocytoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
Doxorubicin
19
Ifosfamide
12
Radiotherapy
11
pembrolizumab
6
Nivolumab
6
Ipilimumab
6
pazopanib
4
Specimen Handling
4
Radiation
4
Gemcitabine
4
Docetaxel
4
CTLA-4 Antigen
4
Biopsy
4
Trabectedin
3
Sunitinib
3
Magnetic Resonance Spectroscopy
3
pegfilgrastim
2
liposomal doxorubicin
2
cabozantinib
2
brostallicin
2
X-Rays
2
Radiotherapy, Conformal
2
Radiation Dose Hypofractionation
2
Methotrexate
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Diathermy
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Quality of Life
×
Sarcoma
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled